ATE342367T1 - Verwendung von fusionsproteinen, deren n- terminaler teil aus einem hirudinderivat besteht, zur herstellung rekombinanter proteine durch sekretion durch hefen - Google Patents

Verwendung von fusionsproteinen, deren n- terminaler teil aus einem hirudinderivat besteht, zur herstellung rekombinanter proteine durch sekretion durch hefen

Info

Publication number
ATE342367T1
ATE342367T1 AT02719782T AT02719782T ATE342367T1 AT E342367 T1 ATE342367 T1 AT E342367T1 AT 02719782 T AT02719782 T AT 02719782T AT 02719782 T AT02719782 T AT 02719782T AT E342367 T1 ATE342367 T1 AT E342367T1
Authority
AT
Austria
Prior art keywords
nucleic acid
yeast
derivative
acid sequence
proteins
Prior art date
Application number
AT02719782T
Other languages
English (en)
Inventor
Paul Habermann
Original Assignee
Sanofi Aventis Deutschland
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis Deutschland filed Critical Sanofi Aventis Deutschland
Application granted granted Critical
Publication of ATE342367T1 publication Critical patent/ATE342367T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C07K14/815—Protease inhibitors from leeches, e.g. hirudin, eglin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/62—Insulins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/80—Vectors or expression systems specially adapted for eukaryotic hosts for fungi
    • C12N15/81—Vectors or expression systems specially adapted for eukaryotic hosts for fungi for yeasts
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
AT02719782T 2001-02-20 2002-02-08 Verwendung von fusionsproteinen, deren n- terminaler teil aus einem hirudinderivat besteht, zur herstellung rekombinanter proteine durch sekretion durch hefen ATE342367T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE10108211A DE10108211A1 (de) 2001-02-20 2001-02-20 Verwendung von Fusionsproteinen, deren N-terminaler Anteil aus einem Hirudinderivat besteht, zur Herstellung rekombinanter Proteine über Sekretion durch Hefen

Publications (1)

Publication Number Publication Date
ATE342367T1 true ATE342367T1 (de) 2006-11-15

Family

ID=7674912

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02719782T ATE342367T1 (de) 2001-02-20 2002-02-08 Verwendung von fusionsproteinen, deren n- terminaler teil aus einem hirudinderivat besteht, zur herstellung rekombinanter proteine durch sekretion durch hefen

Country Status (22)

Country Link
US (1) US20030176673A1 (de)
EP (1) EP1364032B1 (de)
JP (1) JP4199543B2 (de)
KR (1) KR100858833B1 (de)
CN (1) CN1279171C (de)
AT (1) ATE342367T1 (de)
AU (1) AU2002250903B2 (de)
BR (1) BR0207379A (de)
CA (1) CA2439042C (de)
CY (1) CY1106274T1 (de)
DE (2) DE10108211A1 (de)
DK (1) DK1364032T3 (de)
ES (1) ES2272696T3 (de)
HK (1) HK1065068A1 (de)
IL (2) IL157416A0 (de)
MX (1) MXPA03007116A (de)
NO (1) NO331376B1 (de)
NZ (1) NZ527642A (de)
PE (1) PE20020857A1 (de)
PT (1) PT1364032E (de)
WO (1) WO2002070722A1 (de)
ZA (1) ZA200305868B (de)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7638618B2 (en) * 2001-02-20 2009-12-29 Sanofi-Aventis Deutschland Gmbh Nucleic acids encoding a hirudin and pro-insulin as superscretable peptides and for parallel improvement of the exported forms of one or more polypeptides of interest
DE102006031962A1 (de) 2006-07-11 2008-01-17 Sanofi-Aventis Deutschland Gmbh Amidiertes Insulin Glargin
DE102006031955A1 (de) 2006-07-11 2008-01-17 Sanofi-Aventis Deutschland Gmbh Verfahren zur Herstellung von Insulinanaloga mit dibasischem B-Kettenende
CN101970476B (zh) 2008-01-09 2014-08-27 塞诺菲-安万特德国有限公司 具有超延迟时效特征的胰岛素衍生物
DE102008025007A1 (de) 2008-05-24 2009-11-26 Sanofi-Aventis Deutschland Gmbh Neue Insulinderivate mit extrem verzögertem Zeit-/ Wirkungsprofil
DE102008003566A1 (de) 2008-01-09 2009-07-16 Sanofi-Aventis Deutschland Gmbh Neue Insulinderivate mit extrem verzögertem Zeit-/ Wirkungsprofil
EP2229407B1 (de) 2008-01-09 2016-11-16 Sanofi-Aventis Deutschland GmbH Neue insulinderivate mit extrem verzögertem zeit- / wirkungsprofil
RS59913B1 (sr) 2008-10-17 2020-03-31 Sanofi Aventis Deutschland Kombinacija insulina i glp-1-agonista
ES2534191T3 (es) 2009-11-13 2015-04-20 Sanofi-Aventis Deutschland Gmbh Composición farmacéutica que comprende un agonista de GLP-1, una insulina y metionina
KR101337322B1 (ko) 2009-11-13 2013-12-06 사노피-아벤티스 도이칠란트 게엠베하 Ｇｌｐ-1 효능제 및 메티오닌을 포함하는 약제학적 조성물
BR112013004756B1 (pt) 2010-08-30 2020-04-28 Sanofi Aventis Deutschland uso de ave0010 para a fabricação de um medicamento para o tratamento da diabetes melito tipo 2
US9821032B2 (en) 2011-05-13 2017-11-21 Sanofi-Aventis Deutschland Gmbh Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin
PL2750699T3 (pl) 2011-08-29 2015-12-31 Sanofi Aventis Deutschland Kombinacja farmaceutyczna do stosowania w kontroli glikemii u pacjentów z cukrzycą typu 2
TWI559929B (en) 2011-09-01 2016-12-01 Sanofi Aventis Deutschland Pharmaceutical composition for use in the treatment of a neurodegenerative disease
HRP20230470T1 (hr) 2014-12-12 2023-07-21 Sanofi-Aventis Deutschland Gmbh Formulacija fiksnog omjera inzulin glargin/liksisenatid
TWI748945B (zh) 2015-03-13 2021-12-11 德商賽諾菲阿凡提斯德意志有限公司 第２型糖尿病病患治療
TW201705975A (zh) 2015-03-18 2017-02-16 賽諾菲阿凡提斯德意志有限公司 第２型糖尿病病患之治療

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE78294T1 (de) * 1984-03-27 1992-08-15 Transgene Sa Expressionsvektoren fuer hirudin, transformierte zellen und verfahren zur herstellung von hirudin.
US5705355A (en) * 1984-03-27 1998-01-06 Transgene, S.A. Hirudin, pharmaceutical compositions comprising it and their use
DE3738541A1 (de) * 1987-11-13 1989-05-24 Hoechst Ag Verfahren zur isolierung und reinigung von hirudin
US6875589B1 (en) * 1988-06-23 2005-04-05 Hoechst Aktiengesellschaft Mini-proinsulin, its preparation and use
GB8927722D0 (en) * 1989-12-07 1990-02-07 British Bio Technology Proteins and nucleic acids
DE4009268A1 (de) * 1990-03-22 1991-09-26 Consortium Elektrochem Ind Sekretion von hirudinderivaten
CA2072375C (en) * 1990-11-08 2000-01-11 Satoru Misawa Hirudin analog, method of manufacturing thereof and anti-coagulant composition, and secretion vector, transformed microorganisms containing saidvector and manufacturing method of products which is produced from said microorganism
FI92601C (fi) * 1992-03-11 1994-12-12 Marja Makarow Menetelmä hyötyproteiinien erittämiseksi hiivoista
DE19543737A1 (de) * 1995-11-24 1997-05-28 Hoechst Ag Verfahren zur Ultrafiltration von Peptide oder Proteine enthaltender biologischer Matrices
DE19544233A1 (de) * 1995-11-28 1997-06-05 Hoechst Ag Verfahren zur Nutzung des Hefe-ADH II-Promotorsystems zur biotechnologischen Produktion heterologer Proteine in hohen Ausbeuten
AU702567B2 (en) * 1996-03-13 1999-02-25 Novozymes Biopharma Dk A/S Fermentation control
DE10033195A1 (de) * 2000-07-07 2002-03-21 Aventis Pharma Gmbh Bifunktionale Fusionsproteine aus Hirudin und TAP
US7202059B2 (en) * 2001-02-20 2007-04-10 Sanofi-Aventis Deutschland Gmbh Fusion proteins capable of being secreted into a fermentation medium

Also Published As

Publication number Publication date
KR20030074841A (ko) 2003-09-19
EP1364032B1 (de) 2006-10-11
CA2439042A1 (en) 2002-09-12
DE10108211A1 (de) 2002-08-22
CN1526021A (zh) 2004-09-01
NZ527642A (en) 2005-03-24
DK1364032T3 (da) 2007-02-19
ES2272696T3 (es) 2007-05-01
JP4199543B2 (ja) 2008-12-17
NO20033672D0 (no) 2003-08-19
CN1279171C (zh) 2006-10-11
WO2002070722A1 (en) 2002-09-12
BR0207379A (pt) 2004-06-15
EP1364032A1 (de) 2003-11-26
KR100858833B1 (ko) 2008-09-17
PE20020857A1 (es) 2002-11-04
JP2004518446A (ja) 2004-06-24
NO331376B1 (no) 2011-12-12
DE60215315D1 (de) 2006-11-23
AU2002250903B2 (en) 2006-12-07
CY1106274T1 (el) 2011-10-12
ZA200305868B (en) 2005-02-23
IL157416A0 (en) 2004-03-28
CA2439042C (en) 2013-06-18
IL157416A (en) 2009-08-03
US20030176673A1 (en) 2003-09-18
MXPA03007116A (es) 2003-11-18
HK1065068A1 (en) 2005-02-08
PT1364032E (pt) 2007-01-31
DE60215315T2 (de) 2007-05-24
NO20033672L (no) 2003-10-17

Similar Documents

Publication Publication Date Title
ATE342367T1 (de) Verwendung von fusionsproteinen, deren n- terminaler teil aus einem hirudinderivat besteht, zur herstellung rekombinanter proteine durch sekretion durch hefen
Vedvick et al. High-level secretion of biologically active aprotinin from the yeast Pichia pastoris
Lind et al. Novel forms of B‐domain‐deleted recombinant factor VIII molecules: construction and biochemical characterization
KR100227167B1 (ko) 인체혈청알부민의 n-말단 단편을 함유하는 융합단백질
Johansson et al. Surfactant protein B: disulfide bridges, structural properties and kringle similarities
EP0322094B1 (de) N-terminale Fragmente von menschlichem Serumalbumin
AU619553B2 (en) Aprotinin analogues and a process for the production thereof
EP0399666A1 (de) N-terminale Fragmente von menschliches Serumalbumin enthaltenden Fusionsproteinen
CY1105696T1 (el) Υπερεκκρινομενα πεπτιδια, διεργασιες για την παραγωγη τους και παραλληλη βελτιωση του εκκρινομενου ειδους ενος ή περισσοτερων αλλων πεπτιδιων
WO2006062398A3 (en) Methods for the production and secretion of modified peptides
Yamada et al. Separation of recombinant human interleukin-2 and methionyl interleukin-2 produced in Escherichiacoli
FI961238A (fi) Erityssekvenssi heterologisen proteiinin tuottamiseksi hiivassa
DK0755447T3 (da) Rekombinante proteiner af filamentøst hæmagglutinin fra Bordetella, især Bordetella Pertussis, fremgangsmåde til fremstilling heraf samt anvendelse heraf i fremstillingen af fremmede proteiner eller vacciner
ATE527364T1 (de) Polypeptide erhaltend eine modifizierte menschliche serum-albumin sekretions-pre-sequenz mit erhöhtem ausscheidungsertrag
Degryse et al. Addition of a dipeptide spacer significantly improves secretion of ovine trophoblast interferon in yeast
Olins et al. Phosphorylation of high‐and low‐molecular‐mass atrial natriuretic peptide analogs by cyclic AMP‐dependent protein kinase
Okabayashi et al. Secretory production of recombinant urokinase-type plasminogen activator-annexin V chimeras in Pichia pastoris
Przysiecki et al. Characterization of recombinant antistasin secreted by Saccharomyces cerevisiae
Chow et al. Expression of recombinant human glucose-dependent insulinotropic polypeptide in Escherichia coli by sequence-specific proteolysis of a protein A fusion protein
Baron et al. Towards the structure of mosaic proteins: Use of protein expression and NMR techniques
Asakura et al. The enhancement of the extracellular carboxyl-terminal domain of human growth hormone receptor on growth hormone dependent responses of 3T3-F442A cells
CAMPBELL TOWARDS THE STRUCTURE OF MOSAIC PROTEINS: USE OF PROTEIN EXPRESSION AND NMR TECHNIQUES
Charpigny et al. Addition of
JPH0731496A (ja) 血管透過性因子の製造方法

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1364032

Country of ref document: EP